Document is current
Any future updates will be listed below
-
Authors
Xu, Wendan
Berning, Philipp
Erdmann, Tabea
Grau, Michael
Bettazová, Nardjas
Zapukhlyak, Myroslav
Frontzek, Fabian https://orcid.org/0000-0003-1705-3638
Kosnopfel, Corinna https://orcid.org/0000-0002-0910-838X
Lenz, Peter
Grondine, Michael
Willis, Brandon
Lynch, James T.
Klener, Pavel
Hailfinger, Stephan
Barry, Simon T. https://orcid.org/0000-0002-8511-0588
Lenz, Georg https://orcid.org/0000-0002-4728-1693
-
Funding
Funding for this research was provided by:
Agentura Pro Zdravotnický Výzkum České Republiky (AZV NV19-08-00144, AZV NV19-08-00144)
Deutsche Krebshilfe (70113434, 70113427)
- License Information
-
More Information
Article History
Received: 17 June 2022
Revised: 25 October 2022
Accepted: 27 October 2022
First Online: 9 November 2022
Competing interests
: M. Grondine, B.W., J.T.L. and S.T.B. are employees of AstraZeneca. G.L. received research funding from AstraZeneca. G.L. received additional research grants not related to this manuscript from AGIOS, AQUINOX, Bayer, Celgene, Gilead, Janssen, Morphosys, Novartis, Roche, and Verastem. G.L. received honoraria from ADC Therapeutics, Abbvie, Amgen, AstraZeneca, Bayer, BMS, Celgene, Constellation, Genmab, Gilead, Incyte, Janssen, Karyopharm, Morphosys, NanoString, Novartis, and Roche. The remaining authors declare no competing financial interests.
